MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program

First HuCAL-based Antibody to Enter Clinical Trial in Second Indication

15-Dec-2008 - Germany

MorphoSys AG announced that its licensing partner, Centocor R&D Inc., has enrolled a patient in a Phase 2 clinical trial with a HuCAL-derived fully human antibody. A Phase 1 clinical trial using the same antibody in oncology patients was initiated in 2007 and is ongoing. The new trial is in an immunology indication. This achievement marks the first antibody, developed with MorphoSys's core technology, to enter human clinical trials in a second indication with partners. The initiation of the Phase 2 trial and the IND in a new indication trigger clinical milestone payments to MorphoSys.

Other news from the department research and development

Most read news

More news from our other portals

Last viewed contents

Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize

Viruses on the run - ETH Zurich Professor Ari Helenius awarded Benoist Prize

New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future

New approach in the treatment of non-alcoholic fatty liver disease - Resistant starch, such as that found in green bananas, may play an important role in treatment of non-alcoholic fatty liver disease in the future

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe

Evotec Receives a Milestone Payment as Part of its Discovery Alliance with Boehringer Ingelheim

UF study strengthens concerns about long-term use of certain painkillers

Scientists at Almac and Queen’s University Belfast discover novel approach to treat cancer patients.

Restoring chemotherapy sensitivity by boosting microRNA levels

Restoring chemotherapy sensitivity by boosting microRNA levels

Bayer and Onyx Initiate Phase III Trial of Nexavar in Patients with Non-Responsive Thyroid Cancer

Centocor, Inc. - Horsham, USA

Centocor, Inc. - Horsham, USA

Advanced Cell Technology Announces Creation of Human Embryonic Stem Cell Lines Without the Destruction of Embryos - Breakthrough Approach Improves Efficiency to Levels Reported in the Conventional Stem Cell Derivation Techniques

Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration